Related Experiment Video
Updated: Aug 7, 2026
10:46
A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Atrasentan: a rationally designed targeted therapy for cancer
Antonio Jimeno1, Michael Carducci
1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231-1000, USA. ajimeno1@jhmi.edu
Drugs of Today (Barcelona, Spain : 1998)
|June 28, 2006
Summary
Atrasentan targets the endothelin axis, inhibiting prostate cancer progression. This novel agent shows promise in delaying disease advancement and warrants further investigation for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Deregulation of the endothelin axis promotes cancer progression, including proliferation, invasion, and resistance to cell death.
- Key downstream effects include aberrant angiogenesis, abnormal bone formation, and altered pain signaling.
Purpose of the Study:
- To evaluate the efficacy of Atrasentan, a novel endothelin receptor antagonist, in patients with prostate cancer.
- To assess the impact of Atrasentan on biochemical markers and disease progression.
Main Methods:
- Phase III, placebo-controlled clinical trial.
- Administration of Atrasentan to patients with prostate cancer.
- Monitoring of biochemical markers of disease progression and time to progression.
Main Results:
- Atrasentan demonstrated biologic and clinical activity in prostate cancer patients.
- Suppression of biochemical markers of prostate cancer progression was observed.
- A delay in the time to disease progression was achieved compared to placebo.
Conclusions:
- Atrasentan effectively targets the endothelin axis, inhibiting key cancer progression events.
- The drug shows therapeutic potential in managing prostate cancer.
- Further investigation of Atrasentan for prostate and other cancers is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...